Microbiology, Immunology & Molecular Genetics | Faculty | Adjunct | Bernard P. Arulanandam, Ph.D., M.B.A.


Microbiology, Immunology & Molecular Genetics Adjunct Faculty

  Research | Awards | More on Bernard P. Arulanandam

Bernard P. Arulanandam, Ph.D., M.B.A.
Adjunct Professor

Jane and Roland Blumberg Professorship in Biological Sciences
Assistant Vice President for Research Support
Associate Dean of Research for Scientific Innovation
University of Texas at San Antonio
Director, San Antonio Vaccine Development Center
(UTHSCSA School of Medicine, Microbiology, Immunology & Molecular Genetics)

Tel: (210) 458-5492
Fax: (210) 458-5493
Email: Bernard.Arulanandam@utsa.edu


Personal Statement

Dr. Arulanandam is a cellular immunologist and has an established research program (< 15 years) focused on elucidating host-microbial interactions and cellular and molecular mechanisms involved in the induction of immune responses against infectious diseases. Dr. Arulanandam's research program has made significant contributions to the understanding of host-microbe interactions and identifying approaches to induce optimal mocosal protection and immunity. Administratively, he currently serves as the Assistant Vice President for Research and the Director of the South Texas Center for Emerging Infectious Diseases (STCEID), the Center for Infection Genomics (CEIG), and Co-Scientific Director of the San Antonio Vaccine Development Center. Within the last 10 years, Dr. Arulanandam has served as a mentor to 5 Ph.D. students. Dr. Arulanandam has extensively trained and mentored undergraduates and graduate students, who have gone on to successful professional programs and independent careers. Together, he has a proven track record of leadership, funding, publication history and fiscal/administrative management of a research program.


Ph.D., Microbiology & Immunology at the Medical College of Ohio (University of Toledo)


Keywords: Cellular Immunology; Mucosal Defenses; Respiratory Defenses

Research interests:
Mucosal surfaces form the major interface between the host and the environment, and constitute the first line of defense against pathogens. The mammalian mucosal immune system has evolved into an intricate network of tissues, lymphoid and mucus membrane-associated cells and effector mechanisms for host protection. Dr. Arulanandam's laboratory is focused on understanding the basic mechanism(s) of immune defenses at mucosal sites. The specific ongoing projects include the following:

Immunopathogenesis of Chlamydia trachomatis

There currently is no licensed vaccine against Chlamydia trachomatis, the leading cause of sexually transmitted bacterial disease worldwide. They are currently investigating various aspects of Chlamydia-induced pathogenesis utilizing genital and lung bacterial challenge models. The pathology produced by both genital (e.g., PID) and pulmonary infection of newborns (asthma-like consequences such as airway hyper-reactivity) result as a consequence of immunological sequel to the primary or repeated infections with this pathogen.

Respiratory Defenses against Pulmonary Tularemia

Francisella tularensis is an intracellular Gram-negative bacterium that is the causative agent of tularemia. Inhalation of F. tularensis results in severe disease and a high fatality rate in humans. His laboratory has recently shown the involvement of mast cells in early defenses against pulmonary tularemia. They are currently examining the mechanism(s) by which mast cells modulate innate immune defenses against this pathogen, and as a model for other Gram negative bacteria. Moreover, they are characterizing the use of defined F. tularensis mutants as live attenuated vaccine candidates against pneumonic tularemia.

Mucosal Defenses against Acinetobacter baumannii

Acinetobacter baumannii has emerged as an important nosocomial pathogen. There is evidence to suggest that gastrointestinal colonization of A. baumannii in humans precedes the onset of other clinical conditions such as septicemia, pneumonia and wound sepsis, with little known about the interaction of this pathogen with the gastrointestinal (GI) tract. They have developed an oral-gastrointestinal (GI) challenge model with A. baumannii to examine the contribution of mucosal immune defenses against gastrointestinal colonization by this pathogen and the subsequent systemic manifestation of this infection.

Honors & Awards

  • Fellow of the American Association for Advancement of Science (AAAS)- Biological Sciences, 2014
  • Vaccine Council Member of 100, International Society of Vaccines
  • University of Texas System, Chancellor's Entrepreneurship and Innovation Award, 2010
  • University of Texas at San Antonio, President's Distinguished Achievement Award for Research, 2010

Societal Affiliations/Boards- Professional Societies

  • The Royal Society of Medicine
  • Scientific Research Society Sigma Xi
  • National Honor Society Phi Kappa Phi
  • International Cytokine Society
  • Society for Mucosal Immunology
  • American Association of Immunology
  • American Society of Microbiology
  • Chlamydia Basic Research Society

Editorial Board

  • Infection & Immunity Editorial Board
  • Vaccine: Development and Therapy
  • Open Vaccine Journal
  • Frontiers in Microbial Immunology-Review Editor

Selected Publications

Complete List of Publications

[return to top]

This material is based upon the work supported by the Army Research Office of the Department of Defense under Contract No. W911NF-11-1-0136

Updated 05.09.2016